The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus

Clinical Rheumatology

Volumn 34, Issue 2, 2015, Pages 263-271

  Hickman, R A ^a   Hira Kazal, R ^b,c   Yee, C S ^a,d   Toescu, V ^a   Gordon, Caroline ^a,c,e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BARNET HOSPITAL   (United Kingdom)

^c SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^d Doncaster and Bassetlaw Hospitals NHS Foundation Trust   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti CD20; B cell depletion; Lupus; Rituximab; SLE

Indexed keywords

AZATHIOPRINE; CHIMERIC ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; AFRICAN CARIBBEAN; ARTICLE; ASSESSMENT OF HUMANS; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CAUCASIAN; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PARAPLEGIA; PRIORITY JOURNAL; SERUM SICKNESS; SIDE EFFECT; SOUTH ASIAN; SPINAL CORD DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; YOUNG ADULT; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921916082     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2839-0     Document Type: Article

References (32)

1. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358(9):929–939
2. Papadimitraki ED, Boumpas DT (2007) Cytotoxic drug treatment. In. Systemic lupus erythematosus, 1 edn., pp 498–510
3. Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6(5 Pt 1):859–866
4. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18(1):67–73
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277
6. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
7. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86(7):447–458
8. Isenberg DA, Gordon C (2000) From BILAG to BLIPS—disease activity assessment in lupus past, present and future. Lupus 9(9):651–654
9. Cresswell L, Yee CS, Farewell V, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, Toescu V, D’Cruz D, Khamashta MA, Maddison P, Isenberg DA, Gordon C (2009) Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) 48(12):1548–1552
10. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA (2011) The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 50(8):1401–1408
11. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D’Cruz D, Khamashta MA, Maddison P, Gordon C (2009) The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 48(6):691–695
12. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62(8):2458–2466
13. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222–233
14. Fernandez-Nebro A, de la Fuente JL, Carreno L, Izquierdo MG, Tomero E, Rua-Figueroa I, Hernandez-Cruz BE, Narvaez J, Ucar E, Olive A, Zea A, Fernandez-Castro M, Raya-Alvarez E, Pego-Reigosa JM, Freire M, Martinez-Taboada VM, Perez-Venegas J, Sanchez-Atrio AI, Villa-Blanco I, Manrique-Arija S, Lopez-Longo FJ, Carreira PE, Martinez-Perez R, Garcia-Vicuna R (2012) Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 21(10):1063–1076
15. Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64(9):3043–3051
16. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425–437
17. Tavazzi E, Ferrante P, Khalili K (2011) Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 17(12):1776–1780. doi:10.1111/j.1469-0691.2011.03653.x
18. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487
19. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA (2005) Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44(4):561–562
20. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P (2011) B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 63(10):3038–3047
21. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR (2014) The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178
22. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9):767–776
23. Ezeonyeji AN, Isenberg DA (2012) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 51(3):476–481
24. Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC (2009) Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48(8):892–898
25. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A, Caliz RC, Lopez Longo FJ, Munoz-Fernandez S (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Seminars in arthritis and rheumatism
26. Favas C, Isenberg DA (2009) B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat Rev Rheumatol 5(12):711–716
27. Furie R, Looney RJ, Rovin B, Latinis, Kevin M, Appel G, Sanchez-Guerrero J (2009) Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum 60(Suppl 10):1149
28. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226
29. Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2
30. Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20(7):709–716
31. Wofsy D, Hillson JL, Diamond B (2012) Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64(11):3660–3665
32. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379